Co‐clinical trials are also applicable to rare neurodevelopmental disorders associated with variants in the DLG2 gene, as illustrated in the studies analyzed, following a line inspired by strategies previously adopted in genetic syndromes such as APL. This evidence concerns the gene DLG2 and acute promyelocytic leukemia.